TGF-β / Smad Signaling

Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB.

Dalutrafusp alfa (AGEN-1423; GS-1423) is a specific bifunctional antibody against CD73 and TGF-β, which is involved in the immunosuppressive pathway.

Itacnosertib drocholide is an inhibitor of JAK2, ACVR1 (ALK2) and ALK5.

PS432 is a PKC inhibitor with IC50s of 16.9 μM (PKCι) and 18.5 μM (PKCζ), respectively.

BUR1 is a BMP upregulator (EC50: 98 nM) and activates BMPRII signalling.

PD173952 is a tyrosine kinases inhibitor with IC50s of 0.3, 1.7 and 6.6 nM against Lyn, Abl and Csk, respectively.

DJ4 is a ATP-competitive inhibitor of ROCK1/2 (IC50 values:5 and 50 nM) and MRCKα/β (IC50 values:10 and 100 nM).

Rhodblock 6 is a Rho kinase (ROCK) inhibitor that inhibits phospho-MRLC (myosin regulatory light chain) localization.

3-droxy-4-carboxyalkylamidino-5-arylamino-isothiazoles is an inhibitor for bone morphogenetic protein 2 (BMP2) with an IC50 of 2.2 μM.

Trabedersen sodium is an antisense oligodeoxynucleotide that specifically inhibits TGF-β2 (TGF-beta/Smad).

Mongersen sodium is a specific and orally active SMAD7 antisense oligonucleotide.

CDK8-IN-12 is an orally active, potent CDK8 inhibitor with a Ki of 14 nM.

Risvodetinib (IkT-148009) is an oral, selective and brain-penetrant protein tyrosine kinase inhibitor, displaying target efficacy against c-Abl1, c-Abl2/Arg with IC50 values of 33 nM, 14 nM.

THK01 is a potent ROCK2 inhibitor with IC50 values of 5.7 and 923 nM for ROCK2 and ROCK1, respectively.

MY-673 is a colchicine binding site inhibitor (CBSI), that inhibits tubulin polymerization.

THRX-144644 is a Lung-restricted ALK5 inhibitor with an IC50 value of 0.14 nM.

ALK5-IN-34 is an selective orally active activin receptor-like kinase (ALK) inhibitor.

SIAIS100 TFA is a potent BCR-ABL PROTAC degrader with an DC50 value of 2.7 nM.

PRT062607 (P505-15) acetate is an orally available Syk inhibitor (IC50: 1 nM) that inhibits inflammation and induction Apoptosis.

PROTAC BCR-ABL Degrader-1 (compound PROTAC 1) is a PROTAC with a 2-oxoetl linker.

BMPR2-IN-1 (Compound 8a) is a BMPR2 inhibitor with an IC 50 of 506 nM and a K D of 83.5 nM.

BCR-ABL-IN-8 (compound 26f) is a BCR-ABL inhibitor containing trimethoxy group.

DT-6 is an effective TGF-β1 inhibitor.

AKE-72 (compound 5) is a potent inhibitor of Pan-BCR-ABL.